Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Condition: Breast Cancer Intervention: Other: Prosigna PAM-50 assay Sponsors: Dana-Farber Cancer Institute; NanoString Technologies Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Nanotechnology | Neoadjuvant Therapy | Research | Study | Women